Skip to main content
Caplight Logo









Skylark Bio

Skylark Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.skylarkbio.com/

Last Round

Series A

May 6, 2024

Total Funding Raised

$60M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Skylark Bio is a biotechnology company that develops targeted gene therapies aimed at addressing the underlying genetic causes of hearing impairment to improve patient outcomes and quality of life.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyinherited hearing lossAAVadeno-associated virusgenetic medicinemonogenic diseasecapsid engineeringbiotechprecision medicineclinical-stage biotechinner ear therapygene editingdrug developmentaudiology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Skylark Bio Comparables

Compare Skylark Bio with similar companies based on industry and business-model similarity.

Skylark Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sensorion SA
78%
Regeneron Pharmaceuticals
76%
Eli Lilly and Company
74%

Skylark Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 6, 2024

Key People

Founding team and executive leadership

Jodi A. Cook

CEO & President

Executive Team

Skylark Bio Investors

Notable investors and investment history

Skylark Bio investors
InvestorRounds
ARCH Venture PartnersSeries A
ARCH Venture PartnersSeries A
Arkin CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 38% MoM.

  • May 6, 2024

    $60M round led by ARCH Venture Partners

Skylark Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Skylark Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Skylark Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range16
Year Founded2021
Last FundingMay 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?